Tissue plasminogen activator antigen and D-dimer as markers for atherothrombotic risk among healthy postmenopausal women

Circulation

Volumn 110, Issue 3, 2004, Pages 292-300

  Pradhan, Aruna D ^a   LaCroix, Andrea Z ^b   Langer, Robert D ^c   Trevisan, Maurizio ^d   Lewis, Cora E ^e   Hsia, Judith A ^f   Oberman, Albert ^e   Kotchen, Jane M ^g   Ridker, Paul M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e University of Alabama at Birmingham   (United States)

^f GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^g MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Coronary disease; Epidemiology; Fibrinolysis; Thrombosis; Women

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; D DIMER; ESTROGEN; TISSUE PLASMINOGEN ACTIVATOR; TISSUE PLASMINOGEN ACTIVATOR ANTIGEN; UNCLASSIFIED DRUG;

AGE; ARTICLE; ATHEROSCLEROSIS; CASE CONTROL STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DISEASE ASSOCIATION; ESTROGEN THERAPY; ETHNOLOGY; FEMALE; FIBRINOLYSIS; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; NORMAL HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR; SMOKING; THROMBOSIS;

AGED; ANTIGENS; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CORONARY DISEASE; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MIDDLE AGED; POSTMENOPAUSE; PROSPECTIVE STUDIES; RISK FACTORS; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 3242662502     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000134965.73212.A6     Document Type: Article

References (20)

1. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med. 1992;326:310-318.
2. Kooistra T, Schrauwen Y, Arts J, et al. Regulation of endothelial cell t-PA synthesis and release. Int J Hematol. 1994;59:233-255.
3. Nordenhem A, Wiman B. Tissue plasminogen activator (tPA) antigen in plasma: correlation with different tPA/inhibitor complexes. Scand J Clin Lab Invest. 1998;58:475-483.
4. Cohen AF, Burggraaf K, de Boer A, et al. Clearance of plasminogen activator: a major determinant of plasma concentration. Therapeutic and diagnostic implications. Ann NY Acad Sci. 1992;667:443-449.
5. Ridker PM, Vaughan DE, Stampfer MJ, et al. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet. 1993;341:1165-1168.
6. Ridker PM, Hennekens CH, Cerskus A, et al. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation. 1994;90:2236-2240.
7. Thogersen AM, Jansson JH, Boman K, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation. 1998;98:2241-2247.
8. Cushman M, Lemaitre RN, Kuller LH, et al. Fibrinolytic activation markers predict myocardial infarction in the elderly: the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 1999;19:493-498.
9. Danesh J, Whincup P, Walker M, et al. Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation. 2001;103:2323-2327.
10. Folsom AR, Aleksic N, Park E, et al. Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Arterioscler Thromb Vasc Biol. 2001;21:611-617.
11. Ridker PM, Hennekens CH, Stampfer MJ, et al. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet. 1994;343:940-943.
12. Cooper R, Cutler J, Desvigne-Nickens P, et al. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the national conference on cardiovascular disease prevention. Circulation. 2000;102:3137-3147.
13. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials. 1998;19:61-109.
14. Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA. 2002;288:980-987.
15. Gebara OC, Mittleman MA, Sutherland P, et al. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation. 1995;91:1952-1958.
16. Shahar E, Folsom AR, Salomaa VV, et al. Relation of hormone-replacement therapy to measures of plasma fibrinolytic activity: Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation. 1996;93:1970-1975.
17. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, et al. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women: a randomized controlled trial. Arterioscler Thromb Vasc Biol. 1997;17:3071-3078.
18. Koh KK, Mincemoyer R, Bui MN, et al. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med. 1997;336:683-690.
19. Cushman M, Meilahn EN, Psaty BM, et al. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol. 1999;19:893-899.
20. Chandler WL, Alessi MC, Aillaud MF, et al. Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels. Circulation. 1997;96:761-768.